\-\ Texto\\:\\ \ \(0\)\
\-\ well\\ developed\\,\\ well\\ nourished\\ male\ \(1\)\
\-\ raiu\\ \\=0\\.5\\%\ \(0\)\
\-\ tsh\\=\\ 0\\.016\\ uiu\\/ml\ \(0\)\
\-\ t3\\ \\=\\ 234\\ ng\\/dl\ \(0\)\
\-\ steroids\ \(152\)\
\-\ discontinue\\ use\\ of\\ amioradone\\ if\\ clinically\\ feasible\ \(0\)\
\-\ global\\ decreased\\ radiotracer\\ uptake\\ of\\ the\\ thyroid\\ gland\ \(0\)\
\-\ amioradone\\ induced\\ chemical\\ thyrotoxicosis\ \(0\)\
\-\ subacute\\ thyroditis\ \(0\)\
\-\ jod\\-basedow\\ phenomenon\ \(0\)\
\-\ factitious\\ hyperthyroidism\ \(0\)\
\-\ 66\\ year\\ old\\ male\\ with\\ changes\\ in\\ sleeping\\ pattern\\,\\ heat\\ intolerance\\ and\\ increased\\ appetite\\ treated\\ for\\ cardiac\\ arrythmias\\ with\\ amioradone\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ amioradone\\:\\ 0\\.4132274261234296\ \(0\)\
\-\ \\=0\\.5\\:\\ 0\\.13774247537447654\ \(0\)\
\-\ tsh\\=\\:\\ 0\\.13774247537447654\ \(0\)\
\-\ 0\\.016\\:\\ 0\\.13774247537447654\ \(0\)\
\-\ 234\\:\\ 0\\.13774247537447654\ \(0\)\
\-\ thyroditis\\:\\ 0\\.1269120506782274\ \(0\)\
\-\ jod\\-basedow\\:\\ 0\\.1269120506782274\ \(0\)\
\-\ arrythmias\\:\\ 0\\.12057665836403732\ \(0\)\
\-\ discontinue\\:\\ 0\\.11608162598197824\ \(0\)\
\-\ feasible\\:\\ 0\\.11608162598197824\ \(0\)\
\-\ factitious\\:\\ 0\\.11608162598197824\ \(0\)\
\-\ thyrotoxicosis\\:\\ 0\\.09766514166414002\ \(0\)\
\-\ uiu\\/ml\\:\\ 0\\.0954291909822545\ \(0\)\
\-\ raiu\\:\\ 0\\.09173561632500091\ \(0\)\
\-\ ng\\/dl\\:\\ 0\\.09017181228504804\ \(0\)\
\-\ sleeping\\:\\ 0\\.09017181228504804\ \(0\)\
\-\ global\\:\\ 0\\.08875037825058357\ \(0\)\
\-\ phenomenon\\:\\ 0\\.0874475406109109\ \(0\)\
\-\ t3\\:\\ 0\\.0862450243431589\ \(0\)\
\-\ hyperthyroidism\\:\\ 0\\.0862450243431589\ \(0\)\
\-\ heat\\:\\ 0\\.0835903518932308\ \(0\)\
\-\ intolerance\\:\\ 0\\.08310954472656278\ \(0\)\
\-\ chemical\\:\\ 0\\.08219016191370444\ \(0\)\
\-\ nourished\\:\\ 0\\.08049932465370081\ \(0\)\
\-\ induced\\:\\ 0\\.08010373390394628\ \(0\)\
\-\ appetite\\:\\ 0\\.07826337397181529\ \(0\)\
\-\ 66\\:\\ 0\\.07181266748109986\ \(0\)\
\-\ \\=\\:\\ 0\\.07007476693250261\ \(0\)\
\-\ subacute\\:\\ 0\\.06851096289254975\ \(0\)\
\-\ steroids\\:\\ 0\\.06280824809952745\ \(0\)\
\-\ radiotracer\\:\\ 0\\.06230007322912808\ \(0\)\
\-\ well\\:\\ 0\\.060408779780270344\ \(0\)\
\-\ clinically\\:\\ 0\\.05854084721478542\ \(0\)\
\-\ gland\\:\\ 0\\.056865135803010454\ \(0\)\
\-\ thyroid\\:\\ 0\\.054723631951948605\ \(0\)\
\-\ uptake\\:\\ 0\\.053046616010847064\ \(0\)\
\-\ use\\:\\ 0\\.052772486172551605\ \(0\)\
\-\ developed\\:\\ 0\\.05140727320054241\ \(0\)\
\-\ pattern\\:\\ 0\\.05103816154798872\ \(0\)\
\-\ cardiac\\:\\ 0\\.05085682488985891\ \(0\)\
\-\ male\\:\\ 0\\.048287673058983537\ \(0\)\
\-\ treated\\:\\ 0\\.0399664193138103\ \(0\)\
\-\ decreased\\:\\ 0\\.03969931879257124\ \(0\)\
\-\ changes\\:\\ 0\\.03826637462867282\ \(0\)\
\-\ if\\:\\ 0\\.03623036615282243\ \(0\)\
\-\ increased\\:\\ 0\\.03266382471561962\ \(0\)\
\-\ \\%\\:\\ 0\\.03114564114603137\ \(0\)\
\-\ year\\:\\ 0\\.014939144832389293\ \(0\)\
\-\ old\\:\\ 0\\.013670853075972728\ \(0\)\
\-\ for\\:\\ 0\\.011392314822542424\ \(0\)\
\-\ \\,\\:\\ 0\\.00845968954741523\ \(0\)\
\-\ in\\:\\ 0\\.006584331720941483\ \(0\)\
\-\ with\\:\\ 0\\.0036563805028090542\ \(0\)\
\-\ of\\:\\ 0\\.0036407437749371384\ \(0\)\
\-\ and\\:\\ 0\\.0028126407145659133\ \(0\)\
\-\ the\\:\\ 0\\.002160145073494153\ \(0\)\
\-\ \\.\\:\\ 0\\.0005546802515210355\ \(0\)\
